Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$780.92

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $757.50 1
Education $23.42 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $757.50 1
Gilead Sciences, Inc. $11.92 1
Epizyme, Inc., $11.50 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $780.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $757.5011/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788401241 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873991 CMS
Epizyme, Inc., $11.5003/04/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832340057 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

354 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $441.60 12/30/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 691528945
Principal investigator 1 Merck Sharp & Dohme Corporation $1,131.20 12/18/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691478013
Principal investigator 1 Merck Sharp & Dohme Corporation $7,292.00 12/16/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691478017
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,375.00 12/15/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 639760847
Principal investigator 1 Eisai Inc. $565.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547403
Principal investigator 1 Eisai Inc. $450.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547405
Principal investigator 1 Eisai Inc. $565.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547407
Principal investigator 1 Eisai Inc. $899.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547409
Principal investigator 1 Eisai Inc. $450.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547411
Principal investigator 1 Eisai Inc. $565.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547413
Principal investigator 1 Eisai Inc. $580.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547421
Principal investigator 1 Eisai Inc. $15.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547423
Principal investigator 1 Eisai Inc. $899.00 12/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547429
Principal investigator 1 Merck Sharp & Dohme Corporation $46,246.88 12/13/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691528949
Principal investigator 1 Merck Sharp & Dohme Corporation $76.70 12/13/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691528955
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 12/13/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691530017
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $1,340.00 12/11/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
PCYC-1128-CA No dispute reported 06/30/2026 673092347
Principal investigator 1 Genentech, Inc. $664.00 12/06/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 681100997
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 12/06/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691530019
Principal investigator 1 Merck Sharp & Dohme Corporation $568.35 12/02/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691528951
Principal investigator 1 Novartis Pharmaceuticals Corporation $649.40 12/02/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB AS ADJUVANT THERAPY FOR SUBJECTS WITH LOCALIZED OR LOCALLY ADVANCED RCC FOLLOWING NEPHRECTOMY No dispute reported 06/30/2026 640707173
Principal investigator 1 Exelixis Inc. $10,917.40 11/27/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687196527
Principal investigator 1 Merck Sharp & Dohme Corporation $8,388.80 11/22/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691479859
Principal investigator 1 Astellas Pharma Global Development $3,602.00 11/21/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641393213
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,125.00 11/21/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 639760829
Principal investigator 1 Merck Sharp & Dohme Corporation $34,685.16 11/18/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691516591
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 11/18/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691530013
Principal investigator 1 Eisai Inc. $520.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547395
Principal investigator 1 Eisai Inc. $1,200.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547397
Principal investigator 1 Eisai Inc. $1,200.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547399
Principal investigator 1 Eisai Inc. $980.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547401
Principal investigator 1 Eisai Inc. $899.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547415
Principal investigator 1 Eisai Inc. $450.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547417
Principal investigator 1 Eisai Inc. $2,134.00 11/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547419
Principal investigator 1 Incyte Corporation $500.00 11/15/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480427
Principal investigator 1 Incyte Corporation $350.00 11/15/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480429
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $496.80 11/13/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
PCYC-1128-CA No dispute reported 06/30/2026 673092339
Principal investigator 1 Merck Sharp & Dohme Corporation $13,565.60 11/06/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691530009
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,000.00 11/05/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639760823
Principal investigator 1 Dynavax Technologies Corporation $6,876.00 10/28/2019 Non-covered Recipient Entity
Oncology Hematology West
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696041061
Principal investigator 1 Merck Sharp & Dohme Corporation $3,427.60 10/25/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691486039
Principal investigator 1 Merck Sharp & Dohme Corporation $261.30 10/18/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691479187
Principal investigator 1 Merck Sharp & Dohme Corporation $111.60 10/17/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 691476957
Principal investigator 1 Merck Sharp & Dohme Corporation $74.40 10/17/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 691479191
Principal investigator 1 Eisai Inc. $565.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547355
Principal investigator 1 Eisai Inc. $899.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547357
Principal investigator 1 Eisai Inc. $450.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547359
Principal investigator 1 Eisai Inc. $565.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547361
Principal investigator 1 Eisai Inc. $956.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547389
Principal investigator 1 Eisai Inc. $899.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547391
Principal investigator 1 Eisai Inc. $450.00 10/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547393
Principal investigator 1 Incyte Corporation $1,063.00 10/15/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480425
Principal investigator 1 Merck Sharp & Dohme Corporation $216.78 10/15/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691478819
Principal investigator 1 Exelixis Inc. $221.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198593
Principal investigator 1 Exelixis Inc. $1,495.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198599
Principal investigator 1 Exelixis Inc. $5,850.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198603
Principal investigator 1 Exelixis Inc. $65.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198607
Principal investigator 1 Exelixis Inc. $12,500.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198609
Principal investigator 1 Exelixis Inc. $1,500.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198613
Principal investigator 1 Exelixis Inc. $260.00 10/10/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 687198619
Principal investigator 1 Merck Sharp & Dohme Corporation $7,292.00 10/04/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691482759
Principal investigator 1 Astellas Pharma Global Development $5,127.00 09/26/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641393205
Principal investigator 1 AstraZeneca AB $53,193.26 09/26/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer No dispute reported 06/30/2026 684998251
Principal investigator 1 Merck Sharp & Dohme Corporation $9,246.80 09/25/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441067
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $135.74 09/24/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Phase III Adjuvant Melanoma Stage II B C Opdivo Mono No dispute reported 06/30/2026 639760853
Principal investigator 1 Dynavax Technologies Corporation $3,000.00 09/23/2019 Non-covered Recipient Entity
Oncology Hematology West
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696041035
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,264.00 09/20/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every 2 Weeks. No dispute reported 06/30/2026 639760837
Principal investigator 1 PFIZER INC. $23,865.04 09/17/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES No dispute reported 06/30/2026 671693953
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $614.20 09/16/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 639760849
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 09/16/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441431
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547327
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547329
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547331
Principal investigator 1 Eisai Inc. $899.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547333
Principal investigator 1 Eisai Inc. $450.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547335
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547345
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547347
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547349
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547351
Principal investigator 1 Eisai Inc. $565.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547353
Principal investigator 1 Eisai Inc. $899.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547383
Principal investigator 1 Eisai Inc. $450.00 09/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547385
Principal investigator 1 Janssen Research & Development, LLC $604.00 09/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255311
Principal investigator 1 Janssen Research & Development, LLC $707.00 09/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255313
Principal investigator 1 Janssen Research & Development, LLC $589.00 09/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255319
Principal investigator 1 Janssen Research & Development, LLC $589.00 09/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255321
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $3,220.00 09/12/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
PCYC-1128-CA No dispute reported 06/30/2026 673092187
Principal investigator 1 Incyte Corporation $42.75 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480387
Principal investigator 1 Incyte Corporation $59.40 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480389
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480391
Principal investigator 1 Incyte Corporation $14.25 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480393
Principal investigator 1 Incyte Corporation $1.00 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480395
Principal investigator 1 Incyte Corporation $17.55 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480397
Principal investigator 1 Incyte Corporation $19.10 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480399
Principal investigator 1 Incyte Corporation $0.44 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480401
Principal investigator 1 Incyte Corporation $25.07 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480403
Principal investigator 1 Incyte Corporation $42.75 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480405
Principal investigator 1 Incyte Corporation $42.75 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480407
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480409
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480411
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480413
Principal investigator 1 Incyte Corporation $19.10 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480415
Principal investigator 1 Incyte Corporation $19.10 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480417
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480419
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480421
Principal investigator 1 Incyte Corporation $28.50 09/10/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480423
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691439959
Principal investigator 1 Merck Sharp & Dohme Corporation $14.06 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440421
Principal investigator 1 Merck Sharp & Dohme Corporation $0.45 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440495
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440599
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440605
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440609
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441227
Principal investigator 1 Merck Sharp & Dohme Corporation $5.22 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441530
Principal investigator 1 Merck Sharp & Dohme Corporation $34.35 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441781
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441791
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691442097
Principal investigator 1 Merck Sharp & Dohme Corporation $0.40 09/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691442785
Principal investigator 1 Merck Sharp & Dohme Corporation $77.38 08/22/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691479195
Principal investigator 1 Merck Sharp & Dohme Corporation $244.10 08/19/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 691539739
Principal investigator 1 Merck Sharp & Dohme Corporation $225.50 08/17/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 691478823
Principal investigator 1 Merck Sharp & Dohme Corporation $9,284.00 08/16/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441071
Principal investigator 1 Eisai Inc. $580.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547337
Principal investigator 1 Eisai Inc. $580.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547339
Principal investigator 1 Eisai Inc. $1,200.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547341
Principal investigator 1 Eisai Inc. $1,200.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547343
Principal investigator 1 Eisai Inc. $899.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547363
Principal investigator 1 Eisai Inc. $450.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547365
Principal investigator 1 Eisai Inc. $899.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547367
Principal investigator 1 Eisai Inc. $450.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547369
Principal investigator 1 Eisai Inc. $899.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547371
Principal investigator 1 Eisai Inc. $450.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547373
Principal investigator 1 Eisai Inc. $899.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547375
Principal investigator 1 Eisai Inc. $450.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547377
Principal investigator 1 Eisai Inc. $899.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547379
Principal investigator 1 Eisai Inc. $450.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547381
Principal investigator 1 Eisai Inc. $85.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547387
Principal investigator 1 Eisai Inc. $85.00 08/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547425
Principal investigator 1 Janssen Research & Development, LLC $555.00 08/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255315
Principal investigator 1 Janssen Research & Development, LLC $589.00 08/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255317
Principal investigator 1 Merck Sharp & Dohme Corporation $5,425.00 08/12/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441059
Principal investigator 1 PFIZER INC. $7,500.00 08/06/2019 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 671666655
Principal investigator 1 PFIZER INC. $7,370.00 08/06/2019 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 671666749
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $554.40 08/05/2019 Non-covered Recipient Entity
Us Oncology Reserch Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 629159893
Principal investigator 1 Astellas Pharma Global Development $140.00 07/25/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641393197
Principal investigator 1 Merck Sharp & Dohme Corporation $4,444.00 07/24/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440985
Principal investigator 1 Eisai Inc. $956.00 07/17/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547313
Principal investigator 1 Merck Sharp & Dohme Corporation $32,478.72 07/17/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691432057
Principal investigator 1 Merck Sharp & Dohme Corporation $69,370.32 07/17/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691443575
Principal investigator 1 Exelixis Inc. $1,950.00 07/16/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199581
Principal investigator 1 Exelixis Inc. $130.00 07/16/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199585
Principal investigator 1 Exelixis Inc. $910.00 07/16/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199587
Principal investigator 1 Exelixis Inc. $7,500.00 07/16/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199589
Principal investigator 1 Exelixis Inc. $2,000.00 07/16/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199611
Principal investigator 1 Exelixis Inc. $390.00 07/16/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199613
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 07/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440968
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $500.00 07/11/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
PCYC-1128-CA No dispute reported 06/30/2026 673092193
Principal investigator 1 Merck Sharp & Dohme Corporation $148.85 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691440227
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441451
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441537
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441787
Principal investigator 1 Merck Sharp & Dohme Corporation $22.62 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441814
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441893
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691442101
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691442199
Principal investigator 1 Merck Sharp & Dohme Corporation $8.88 07/10/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691442205
Principal investigator 1 Merck Sharp & Dohme Corporation $474.00 07/05/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691469437
Principal investigator 1 Merck Sharp & Dohme Corporation $7,204.00 07/03/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691441063
Principal investigator 1 Merck Sharp & Dohme Corporation $27,131.20 06/28/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691441439
Principal investigator 1 Merck Sharp & Dohme Corporation $3,646.00 06/26/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691350085
Principal investigator 1 Merck Sharp & Dohme Corporation $54,262.40 06/26/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma No dispute reported 06/30/2026 691443571
Principal investigator 1 PFIZER INC. $70,000.00 06/26/2019 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 671656293
Principal investigator 1 Merck Sharp & Dohme Corporation $3,646.00 06/24/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691350081
Principal investigator 1 Merck Sharp & Dohme Corporation $14,066.40 06/21/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691350077
Principal investigator 1 PFIZER INC. $2,965.00 06/18/2019 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 671656375
Principal investigator 1 Eisai Inc. $899.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547299
Principal investigator 1 Eisai Inc. $450.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547301
Principal investigator 1 Eisai Inc. $899.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547303
Principal investigator 1 Eisai Inc. $899.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547305
Principal investigator 1 Eisai Inc. $450.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547307
Principal investigator 1 Eisai Inc. $899.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547309
Principal investigator 1 Eisai Inc. $450.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547311
Principal investigator 1 Eisai Inc. $450.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547315
Principal investigator 1 Eisai Inc. $565.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547317
Principal investigator 1 Eisai Inc. $565.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547319
Principal investigator 1 Eisai Inc. $899.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547321
Principal investigator 1 Eisai Inc. $450.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547323
Principal investigator 1 Eisai Inc. $565.00 06/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547325
Principal investigator 1 Incyte Corporation $5,449.00 06/15/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations No dispute reported 06/30/2026 666480385
Principal investigator 1 Merck Sharp & Dohme Corporation $5,275.00 06/14/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691350089
Principal investigator 1 PFIZER INC. $23,865.04 06/09/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES No dispute reported 06/30/2026 671656195
Principal investigator 1 Merck Sharp & Dohme Corporation $241.72 06/04/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691480423
Principal investigator 1 Genentech, Inc. $979.50 05/30/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 681087515
Principal investigator 1 Merck Sharp & Dohme Corporation $2,863.45 05/30/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 691494627
Principal investigator 1 Genentech, Inc. $4,510.50 05/23/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 681080293
Principal investigator 1 Merck Sharp & Dohme Corporation $9,348.80 05/22/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691317133
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $614.00 05/21/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 639760827
Principal investigator 1 PFIZER INC. $1,496.82 05/14/2019 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 671656127
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 05/13/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691439783
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 05/09/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 691439781
Principal investigator 1 Merck Sharp & Dohme Corporation $357.24 05/09/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 691441443
Principal investigator 1 Merck Sharp & Dohme Corporation $43,304.96 05/09/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 691441447
Principal investigator 1 Merck Sharp & Dohme Corporation $783.60 05/09/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 691443579
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691387693
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691388151
Principal investigator 1 Merck Sharp & Dohme Corporation $30.34 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691388329
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691388753
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691388907
Principal investigator 1 Merck Sharp & Dohme Corporation $6.96 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691388909
Principal investigator 1 Merck Sharp & Dohme Corporation $83.00 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691397223
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691414885
Principal investigator 1 Merck Sharp & Dohme Corporation $91.60 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691415999
Principal investigator 1 Merck Sharp & Dohme Corporation $0.80 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691416145
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 05/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691416799
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,093.51 05/07/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 639760819
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,000.00 05/01/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639760821
Principal investigator 1 Merck Sharp & Dohme Corporation $1,066.90 04/26/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 691480413
Principal investigator 1 Merck Sharp & Dohme Corporation $15,651.80 04/24/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691317039
Principal investigator 1 Merck Sharp & Dohme Corporation $21,704.96 04/23/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691441436
Principal investigator 1 Astellas Pharma Global Development $140.00 04/18/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641393189
Principal investigator 1 Eisai Inc. $899.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547173
Principal investigator 1 Eisai Inc. $565.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547175
Principal investigator 1 Eisai Inc. $450.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547177
Principal investigator 1 Eisai Inc. $565.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547179
Principal investigator 1 Eisai Inc. $565.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547181
Principal investigator 1 Eisai Inc. $899.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547183
Principal investigator 1 Eisai Inc. $450.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547185
Principal investigator 1 Eisai Inc. $565.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547187
Principal investigator 1 Eisai Inc. $899.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547189
Principal investigator 1 Eisai Inc. $956.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547191
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547193
Principal investigator 1 Eisai Inc. $400.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547195
Principal investigator 1 Eisai Inc. $899.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547211
Principal investigator 1 Eisai Inc. $450.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547213
Principal investigator 1 Eisai Inc. $565.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547215
Principal investigator 1 Eisai Inc. $400.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547227
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547229
Principal investigator 1 Eisai Inc. $15.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547231
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547233
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547235
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547237
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547239
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547241
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547243
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547245
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547247
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547249
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547251
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547253
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547255
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547257
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547259
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547261
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547263
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547265
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547267
Principal investigator 1 Eisai Inc. $400.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547269
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547271
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547273
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547275
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547277
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547279
Principal investigator 1 Eisai Inc. $200.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547281
Principal investigator 1 Eisai Inc. $899.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547295
Principal investigator 1 Eisai Inc. $450.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547297
Principal investigator 1 Eisai Inc. $450.00 04/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547427
Principal investigator 1 Janssen Research & Development, LLC $707.00 04/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255299
Principal investigator 1 Janssen Research & Development, LLC $175.00 04/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255301
Principal investigator 1 Janssen Research & Development, LLC $175.00 04/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255303
Principal investigator 1 Janssen Research & Development, LLC $175.00 04/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255305
Principal investigator 1 Janssen Research & Development, LLC $707.00 04/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255307
Principal investigator 1 Janssen Research & Development, LLC $175.00 04/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255309
Principal investigator 1 Merck Sharp & Dohme Corporation $1,290.10 04/11/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 691480419
Principal investigator 1 Merck Sharp & Dohme Corporation $4,996.00 04/03/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691317045
Principal investigator 1 Merck Sharp & Dohme Corporation $8,312.00 04/03/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691317127
Principal investigator 1 Array BioPharma Inc. $500.00 04/02/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870789
Principal investigator 1 Array BioPharma Inc. $875.00 04/02/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870791
Principal investigator 1 Array BioPharma Inc. $1,950.00 04/02/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870793
Principal investigator 1 Merck Sharp & Dohme Corporation $2,342.00 03/18/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691317043
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,528.93 03/15/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Phase IIB Prostate Combos Doxetaxel PARP Enza No dispute reported 06/30/2026 639760845
Principal investigator 1 Eisai Inc. $899.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547197
Principal investigator 1 Eisai Inc. $450.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547199
Principal investigator 1 Eisai Inc. $899.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547201
Principal investigator 1 Eisai Inc. $450.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547203
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547205
Principal investigator 1 Eisai Inc. $899.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547207
Principal investigator 1 Eisai Inc. $450.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547209
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547217
Principal investigator 1 Eisai Inc. $899.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547219
Principal investigator 1 Eisai Inc. $450.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547221
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547223
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547225
Principal investigator 1 Eisai Inc. $580.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547283
Principal investigator 1 Eisai Inc. $2,130.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547285
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547287
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547289
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547291
Principal investigator 1 Eisai Inc. $565.00 03/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547293
Principal investigator 1 Merck Sharp & Dohme Corporation $16,246.14 03/12/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691289501
Principal investigator 1 Merck Sharp & Dohme Corporation $132.00 03/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691397595
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,541.00 03/06/2019 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 No dispute reported 06/30/2026 639760843
Principal investigator 1 Merck Sharp & Dohme Corporation $21,723.04 03/06/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C.
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) inSubjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive toBacillus Calmette-Guerin (BCG) Therapy No dispute reported 06/30/2026 691289391
Principal investigator 1 PFIZER INC. $1,561.66 03/05/2019 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 671656125
Principal investigator 1 Merck Sharp & Dohme Corporation $9,756.40 02/25/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691317200
Principal investigator 1 PFIZER INC. $1,014.55 02/20/2019 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 671656295
Principal investigator 1 Eisai Inc. $980.00 02/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547167
Principal investigator 1 Eisai Inc. $1,200.00 02/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547169
Principal investigator 1 Eisai Inc. $1,200.00 02/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547171
Principal investigator 1 Array BioPharma Inc. $425.00 02/14/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870785
Principal investigator 1 Array BioPharma Inc. $325.00 02/14/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870787
Principal investigator 1 Astellas Pharma Global Development $3,462.00 02/14/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641393185
Principal investigator 1 Merck Sharp & Dohme Corporation $67,500.00 02/13/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 1b Dose Escalation Study to Assess the Safety of AFM13in Combination with Pembrolizumab in Patients with Relapsedor Refractory Classical Hodgkin Lymphoma No dispute reported 06/30/2026 691312649
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $1,231.20 02/07/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
PCYC-1128-CA No dispute reported 06/30/2026 673091605
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,267.00 02/06/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every No dispute reported 06/30/2026 639760835
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $554.40 02/04/2019 Non-covered Recipient Entity
Us Oncology Reserch Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 629160211
Principal investigator 1 PFIZER INC. $6,625.16 02/02/2019 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 671656297
Principal investigator 1 Novocure Inc. $1,800.00 01/31/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C. Nebraska Cancer Specialists
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 694525957
Principal investigator 1 Novocure Inc. $1,573.00 01/31/2019 Non-covered Recipient Entity
Oncology Hematology West, P.C. Nebraska Cancer Specialists
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 694525959
Principal investigator 1 Dynavax Technologies Corporation $2,689.00 01/28/2019 Non-covered Recipient Entity
Oncology Hematology West
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040877
Principal investigator 1 Array BioPharma Inc. $625.00 01/24/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870783
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,510.50 01/24/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 639760831
Principal investigator 1 TESARO, Inc. $13,518.08 01/24/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A PHASE III TRIAL OF NIRAPARIB VERSUS PHYSICIAN'S CHOICE IN HER2 NEGATIVE, GERMLINE BRCA MUTATION-POSITIVE BREAST CANCER PATIENTS BRAVO No dispute reported 06/30/2026 689409841
Principal investigator 1 PFIZER INC. $3,305.48 01/23/2019 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 671656207
Principal investigator 1 Merck Sharp & Dohme Corporation $14,492.40 01/21/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691309315
Principal investigator 1 Array BioPharma Inc. $600.00 01/15/2019 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors No dispute reported 06/30/2026 704870781
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,400.00 01/15/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
SUSTAIN, event driven trial No dispute reported 06/30/2026 639760825
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,894.00 01/15/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Nivo RCC Safety Trial No dispute reported 06/30/2026 639760833
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,757.00 01/15/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Nivo Dose Frequency Optimization Lung Trial No dispute reported 06/30/2026 639760839
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,648.00 01/15/2019 Non-covered Recipient Entity
Nebraska Cancer Specialists
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 639760841
Principal investigator 1 Eisai Inc. $899.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547135
Principal investigator 1 Eisai Inc. $899.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547137
Principal investigator 1 Eisai Inc. $899.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547139
Principal investigator 1 Eisai Inc. $899.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547141
Principal investigator 1 Eisai Inc. $565.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547143
Principal investigator 1 Eisai Inc. $565.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547145
Principal investigator 1 Eisai Inc. $450.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547147
Principal investigator 1 Eisai Inc. $450.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547149
Principal investigator 1 Eisai Inc. $899.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547151
Principal investigator 1 Eisai Inc. $565.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547153
Principal investigator 1 Eisai Inc. $899.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547155
Principal investigator 1 Eisai Inc. $450.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547157
Principal investigator 1 Eisai Inc. $450.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547159
Principal investigator 1 Eisai Inc. $450.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547161
Principal investigator 1 Eisai Inc. $450.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547163
Principal investigator 1 Eisai Inc. $956.00 01/15/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 702547165
Principal investigator 1 Janssen Research & Development, LLC $707.00 01/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255295
Principal investigator 1 Janssen Research & Development, LLC $707.00 01/15/2019 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 654255297
Principal investigator 1 Novartis Pharmaceuticals Corporation $146.52 01/15/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETINIB VERSUS PLACEBO DABRAFENIB AND TRAMETINIB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA No dispute reported 06/30/2026 640721671
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $49,413.00 01/14/2019 Non-covered Recipient Entity
Us Oncology Res Llc
Phase IIB Prostate Combos PARP Enza Chemo No dispute reported 06/30/2026 639760851
Principal investigator 1 Eli Lilly and Company $5,000.00 01/14/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 No dispute reported 06/30/2026 654299343
Principal investigator 1 Merck Sharp & Dohme Corporation $371.54 01/11/2019 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 691480425
Principal investigator 1 Merck Sharp & Dohme Corporation $21,661.52 01/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691289504
Principal investigator 1 Merck Sharp & Dohme Corporation $8,312.00 01/08/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 691309317
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,821.52 01/01/2019 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 640723123